KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 75 filers reported holding KALA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.12 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $6,000 | – | 30,842 | +1056.4% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 2,667 | -87.9% | 0.00% | – |
| Q3 2021 | $119,000 | +2.6% | 22,002 | 0.0% | 0.00% | – |
| Q2 2021 | $116,000 | -26.6% | 22,002 | -6.2% | 0.00% | – |
| Q1 2021 | $158,000 | -48.2% | 23,450 | -48.0% | 0.00% | – |
| Q4 2020 | $305,000 | +70.4% | 45,072 | +163.2% | 0.00% | – |
| Q2 2020 | $179,000 | +105.7% | 17,123 | +71.8% | 0.00% | – |
| Q1 2020 | $87,000 | +38.1% | 9,966 | -41.8% | 0.00% | – |
| Q4 2019 | $63,000 | +28.6% | 17,116 | +32.0% | 0.00% | – |
| Q3 2019 | $49,000 | +512.5% | 12,969 | +899.2% | 0.00% | – |
| Q2 2019 | $8,000 | +166.7% | 1,298 | +70.1% | 0.00% | – |
| Q4 2018 | $3,000 | -85.7% | 763 | -65.7% | 0.00% | – |
| Q3 2018 | $21,000 | +2000.0% | 2,226 | +3035.2% | 0.00% | – |
| Q1 2018 | $1,000 | – | 71 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 771,790 | $5,788,000 | 5.46% |
| RA Capital Management | 10,874,613 | $81,560,000 | 1.49% |
| Mesirow Financial Investment Management, Inc. | 36,445 | $273,000 | 1.17% |
| Samsara BioCapital, LLC | 451,162 | $3,384,000 | 0.94% |
| Parkman Healthcare Partners LLC | 310,053 | $2,325,000 | 0.62% |
| Orbimed Advisors | 5,465,030 | $40,988,000 | 0.52% |
| Eventide Asset Management | 3,450,000 | $25,875,000 | 0.51% |
| Vivo Capital, LLC | 786,883 | $5,902,000 | 0.34% |
| Ikarian Capital, LLC | 451,531 | $3,387,000 | 0.24% |
| Matisse Capital | 50,300 | $377,000 | 0.15% |